ArriVent BioPharma

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research and development (R&D) and commercialization cooperation agreement with ArriVent BioPharma, Inc. (NASDAQ: AVBP), a U.S. biopharmaceutical firm. The collaboration aims to jointly discover, develop, and commercialize innovative antibody-drug conjugates (ADCs) for oncology treatments. According to…